NovaScan

NovaScan, based in Chicago, IL, at 1623 W Fulton St, specializes in developing advanced technology for better cancer detection and stratification. The company offers products such as MarginScan Skin, which allows dermatologists to perform skin cancer procedures with fast and predictable results. NovaScan’s platform technology is believed to provide significant advantages in soft tissue cancer detection compared to existing alternatives. The company has announced a U.S. distribution agreement with Epredia for the MarginScan device, specifically for non-melanoma skin cancer detection. NovaScan actively participates in leading medical conferences worldwide, presenting research on lung and gastrointestinal cancers. The company has received a competitive award for pancreatic cancer research in collaboration with Dr. Paul Grippo. NovaScan has developed nsCanary, a product for real-time biopsy assessment in pancreatic, biliary, and lung applications, with a product launch anticipated in 2025. Additionally, NovaScan has created predictive technology that can inform on the aggressiveness of cancer and the predisposition of metastasis, as well as an electrical mammogram technology that shows promise in reducing false positives and negatives in breast cancer detection.